Cisplatin as initial chemotherapy in ovarian carcinosarcomas: A Gynecologic Oncology Group study

J. Tate Thigpen, John A. Blessing, Koenraad De Geest, Katherine Y. Look, Howard D. Homesley

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Objectives. Carcinosarcomas of the ovary are rare; hence, although most patients recur after surgical resection or have metastatic disease at the time of diagnosis, only anecdotal information is available concerning the activity of cytotoxic drugs against these lesions. The Gynecologic Oncology Group (GOG) initiated a concerted effort to study cytotoxic therapy for these cancers in 1976. This report presents data on cisplatin, the first of the agents to be studied in this disease. Methods. One hundred thirty-six eligible patients with ovarian carcinosarcoma received cisplatin (50 mg/m2) every 3 weeks until disease progression or unacceptable toxicity. Results. Among 44 patients evaluable for response, one complete (2%) and eight partial (18%) responses resulted. An additional 10 (23%) patients exhibited stable disease, while 25 (57%) had increasing disease. Median progression-free survival in 130 patients evaluable for this endpoint was 5.2 months. Median survival in the same 130 patients was 11.7 months. Adverse effects ≥grade 2 among the 132 patients evaluable for toxicity included leukopenia (14%), neutropenia (17%), thrombocytopenia (2%), anemia (10%), nausea and vomiting (40%), azotemia (3%), neurotoxicity (4%), fever (2%), and tinnitus (1%). Conclusions. These data provide the first objective evidence that cisplatin is active as an initial therapy for patients who have carcinosarcoma of the ovary. The overall response rate (20%) is similar to that seen in carcinosarcomas of the uterus.

Original languageEnglish (US)
Pages (from-to)336-339
Number of pages4
JournalGynecologic Oncology
Volume93
Issue number2
DOIs
StatePublished - May 2004
Externally publishedYes

Fingerprint

Carcinosarcoma
Cisplatin
Drug Therapy
Ovary
Azotemia
Tinnitus
Leukopenia
Neutropenia
Nausea
Disease-Free Survival
Uterus
Vomiting
Disease Progression
Anemia
Fever
Survival

Keywords

  • Chemotherapy
  • Cisplatin
  • Ovarian carcinosarcomas

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Cisplatin as initial chemotherapy in ovarian carcinosarcomas : A Gynecologic Oncology Group study. / Thigpen, J. Tate; Blessing, John A.; De Geest, Koenraad; Look, Katherine Y.; Homesley, Howard D.

In: Gynecologic Oncology, Vol. 93, No. 2, 05.2004, p. 336-339.

Research output: Contribution to journalArticle

Thigpen, J. Tate ; Blessing, John A. ; De Geest, Koenraad ; Look, Katherine Y. ; Homesley, Howard D. / Cisplatin as initial chemotherapy in ovarian carcinosarcomas : A Gynecologic Oncology Group study. In: Gynecologic Oncology. 2004 ; Vol. 93, No. 2. pp. 336-339.
@article{5cb3ff5ea4a345ad97ea9bc993d909c1,
title = "Cisplatin as initial chemotherapy in ovarian carcinosarcomas: A Gynecologic Oncology Group study",
abstract = "Objectives. Carcinosarcomas of the ovary are rare; hence, although most patients recur after surgical resection or have metastatic disease at the time of diagnosis, only anecdotal information is available concerning the activity of cytotoxic drugs against these lesions. The Gynecologic Oncology Group (GOG) initiated a concerted effort to study cytotoxic therapy for these cancers in 1976. This report presents data on cisplatin, the first of the agents to be studied in this disease. Methods. One hundred thirty-six eligible patients with ovarian carcinosarcoma received cisplatin (50 mg/m2) every 3 weeks until disease progression or unacceptable toxicity. Results. Among 44 patients evaluable for response, one complete (2{\%}) and eight partial (18{\%}) responses resulted. An additional 10 (23{\%}) patients exhibited stable disease, while 25 (57{\%}) had increasing disease. Median progression-free survival in 130 patients evaluable for this endpoint was 5.2 months. Median survival in the same 130 patients was 11.7 months. Adverse effects ≥grade 2 among the 132 patients evaluable for toxicity included leukopenia (14{\%}), neutropenia (17{\%}), thrombocytopenia (2{\%}), anemia (10{\%}), nausea and vomiting (40{\%}), azotemia (3{\%}), neurotoxicity (4{\%}), fever (2{\%}), and tinnitus (1{\%}). Conclusions. These data provide the first objective evidence that cisplatin is active as an initial therapy for patients who have carcinosarcoma of the ovary. The overall response rate (20{\%}) is similar to that seen in carcinosarcomas of the uterus.",
keywords = "Chemotherapy, Cisplatin, Ovarian carcinosarcomas",
author = "Thigpen, {J. Tate} and Blessing, {John A.} and {De Geest}, Koenraad and Look, {Katherine Y.} and Homesley, {Howard D.}",
year = "2004",
month = "5",
doi = "10.1016/j.ygyno.2004.01.007",
language = "English (US)",
volume = "93",
pages = "336--339",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Cisplatin as initial chemotherapy in ovarian carcinosarcomas

T2 - A Gynecologic Oncology Group study

AU - Thigpen, J. Tate

AU - Blessing, John A.

AU - De Geest, Koenraad

AU - Look, Katherine Y.

AU - Homesley, Howard D.

PY - 2004/5

Y1 - 2004/5

N2 - Objectives. Carcinosarcomas of the ovary are rare; hence, although most patients recur after surgical resection or have metastatic disease at the time of diagnosis, only anecdotal information is available concerning the activity of cytotoxic drugs against these lesions. The Gynecologic Oncology Group (GOG) initiated a concerted effort to study cytotoxic therapy for these cancers in 1976. This report presents data on cisplatin, the first of the agents to be studied in this disease. Methods. One hundred thirty-six eligible patients with ovarian carcinosarcoma received cisplatin (50 mg/m2) every 3 weeks until disease progression or unacceptable toxicity. Results. Among 44 patients evaluable for response, one complete (2%) and eight partial (18%) responses resulted. An additional 10 (23%) patients exhibited stable disease, while 25 (57%) had increasing disease. Median progression-free survival in 130 patients evaluable for this endpoint was 5.2 months. Median survival in the same 130 patients was 11.7 months. Adverse effects ≥grade 2 among the 132 patients evaluable for toxicity included leukopenia (14%), neutropenia (17%), thrombocytopenia (2%), anemia (10%), nausea and vomiting (40%), azotemia (3%), neurotoxicity (4%), fever (2%), and tinnitus (1%). Conclusions. These data provide the first objective evidence that cisplatin is active as an initial therapy for patients who have carcinosarcoma of the ovary. The overall response rate (20%) is similar to that seen in carcinosarcomas of the uterus.

AB - Objectives. Carcinosarcomas of the ovary are rare; hence, although most patients recur after surgical resection or have metastatic disease at the time of diagnosis, only anecdotal information is available concerning the activity of cytotoxic drugs against these lesions. The Gynecologic Oncology Group (GOG) initiated a concerted effort to study cytotoxic therapy for these cancers in 1976. This report presents data on cisplatin, the first of the agents to be studied in this disease. Methods. One hundred thirty-six eligible patients with ovarian carcinosarcoma received cisplatin (50 mg/m2) every 3 weeks until disease progression or unacceptable toxicity. Results. Among 44 patients evaluable for response, one complete (2%) and eight partial (18%) responses resulted. An additional 10 (23%) patients exhibited stable disease, while 25 (57%) had increasing disease. Median progression-free survival in 130 patients evaluable for this endpoint was 5.2 months. Median survival in the same 130 patients was 11.7 months. Adverse effects ≥grade 2 among the 132 patients evaluable for toxicity included leukopenia (14%), neutropenia (17%), thrombocytopenia (2%), anemia (10%), nausea and vomiting (40%), azotemia (3%), neurotoxicity (4%), fever (2%), and tinnitus (1%). Conclusions. These data provide the first objective evidence that cisplatin is active as an initial therapy for patients who have carcinosarcoma of the ovary. The overall response rate (20%) is similar to that seen in carcinosarcomas of the uterus.

KW - Chemotherapy

KW - Cisplatin

KW - Ovarian carcinosarcomas

UR - http://www.scopus.com/inward/record.url?scp=1942444604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1942444604&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2004.01.007

DO - 10.1016/j.ygyno.2004.01.007

M3 - Article

C2 - 15099942

AN - SCOPUS:1942444604

VL - 93

SP - 336

EP - 339

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -